Tak­ing on gam­ma delta T cells, blue­bird pays $16M for TC Bio­Phar­m's tu­mor in­vad­ing tech plat­form

Gene ther­a­py pi­o­neer blue­bird bio is team­ing up with Scot­land’s TC Bio­Pharm to get its hands on an ex­per­i­men­tal pro­gram in­volv­ing an emerg­ing im­munother­a­py plat­form: CAR-en­gi­neered gam­ma delta T cells.

As part of the deal, blue­bird $BLUE is pay­ing TC Bio­Pharm (TCB) a $16 mil­lion up­front pay­ment, with undis­closed mile­stones and roy­al­ties down the road. TCB will be re­spon­si­ble for de­vel­op­ing tar­gets through Phase I/II, while blue­bird has the ex­clu­sive op­tion to take on fur­ther clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion world­wide.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.